Kazzazi Fawz, Pollard Cleo, Tern Paul, Ayuso-Garcia Alejandro, Gillespie Jack, Thomsen Inesa
University of Cambridge, School of Clinical Medicine, Cambridge, UK.
Polygeia (Global Health Student Think-Tank), Cambridge, UK.
J Pharm Policy Pract. 2017 Oct 4;10:32. doi: 10.1186/s40545-017-0120-z. eCollection 2017.
The UK Pharmaceutical Industry is arguably one of the most important industries to consider in the negotiations following the Brexit vote. Providing tens of thousands of jobs and billions in tax revenue and research investment, the importance of this industry cannot be understated. At stake is the global leadership in the sector, which produces some of the field's most influential basic science and translation work. However, interruptions and losses may occur at multiple levels, affecting patients, researchers, universities, companies and government.
By understanding the current state of pharmaceutical sector, the potential effect of leaving the European Union (EU) on this successful industry can be better understood. This paper aims to address the priorities for negotiations by collating the analyses of professionals in the field, leading companies and non-EU member states.
A government healthcare policy advisor and Chief Science Officer (CSO) for a major pharmaceutical firm were consulted to scope the paper. In these discussions, five key areas were identified: contribution, legislative processes, regulatory processes, research and outcomes, commercial risk. Multiple search engines were utilised for selecting relevant material, predominantly PubMed and Google Scholar. To supplement this information, Government documents were located using the "GOV.UK" publications tool, and interviews and commentaries were found through the Google News search function.
With thorough investigation of the literature, we propose four foundations in the advancement of negotiations. These prioritise: negotiation of 'associated country' status, bilaterally favourable trade agreements, minimal interruption to regulatory bodies and special protection for the movement of workforce in the life sciences industry.
英国制药行业可以说是脱欧公投后谈判中需要考虑的最重要行业之一。该行业提供了数万个工作岗位，带来了数十亿的税收收入和研究投资，其重要性不容小觑。英国制药行业在全球该领域处于领先地位，产出了一些最具影响力的基础科学和转化医学研究成果。然而，脱欧可能在多个层面造成干扰和损失，影响患者、研究人员、大学、企业和政府。
通过了解制药行业的现状，能更好地理解脱离欧盟对这个成功行业可能产生的影响。本文旨在通过整理该领域专业人士、领先企业和非欧盟成员国的分析，阐述谈判的优先事项。
咨询了一位政府医疗政策顾问和一家大型制药公司的首席科学官，以此确定本文的范围。在这些讨论中，确定了五个关键领域：贡献、立法程序、监管程序、研究与成果、商业风险。使用了多个搜索引擎来筛选相关资料，主要是PubMed和谷歌学术。为补充这些信息，利用“英国政府”出版物工具查找政府文件，并通过谷歌新闻搜索功能查找访谈和评论。
通过对文献的全面调查，我们在推进谈判方面提出了四个基础要点。这些要点的优先顺序为：争取“联系国”地位的谈判、双边有利的贸易协定、对监管机构的干扰降至最低以及对生命科学行业劳动力流动的特殊保护。
